Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Puhlmann

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Human Gene Therapy|March 27, 1999
Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapyM Puhlmann, M Gnant, C K Brown, et al.
Der Unfallchirurg|October 1, 1994
[Bridging long tibial shaft defects by partially demineralized bone matrix]K K Hallfeldt, H Stützle, M Puhlmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liverH R Alexander, S K Libutti, D L Bartlett, et al.
Cancer Gene Therapy|March 4, 2000
Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutantM Puhlmann, C K Brown, M Gnant, et al.
Gene Therapy|August 3, 2000
Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regressionJ A McCart, M Puhlmann, J Lee, et al.
Journal of the National Cancer Institute|October 21, 1999
Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastasesM F Gnant, L A Noll, K R Irvine, et al.
Cancer Research|September 24, 1999
Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virusM F Gnant, A C Berger, J Huang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2021
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphomaS Horwitz, O A O'Connor, B Pro, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Human Gene Therapy|March 27, 1999
Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapyM Puhlmann, M Gnant, C K Brown, et al.
Der Unfallchirurg|October 1, 1994
[Bridging long tibial shaft defects by partially demineralized bone matrix]K K Hallfeldt, H Stützle, M Puhlmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liverH R Alexander, S K Libutti, D L Bartlett, et al.
Cancer Gene Therapy|March 4, 2000
Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutantM Puhlmann, C K Brown, M Gnant, et al.
Gene Therapy|August 3, 2000
Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regressionJ A McCart, M Puhlmann, J Lee, et al.
Journal of the National Cancer Institute|October 21, 1999
Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastasesM F Gnant, L A Noll, K R Irvine, et al.
Cancer Research|September 24, 1999
Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virusM F Gnant, A C Berger, J Huang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2021
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphomaS Horwitz, O A O'Connor, B Pro, et al.
Pageof 2